Blood sugar checks are beneficial for those with type 2 diabetes
the ONA take:
Blood sugar self-monitoring benefits patients with type 2 diabetes even if they are not prescribed insulin, according to preliminary findings presented at the American Association of Diabetes Educators annual meeting in New Orleans, LA.
For the small study, researchers enrolled 11 patients with type 2 diabetes and worked with the patients to design personalized, structured self-monitoring blood glucose schedules.
Researchers then taught patients to react to their blood sugar level readings by performing certain interventions, such as going for a walk or eating less.
Results showed that the patients reduced their A1C levels from an average of 7.3% to 6.2% during the the study. The majority of patients received the most benefit from twice daily self-monitoring.
"Participants in this study said that sticking to a regular [self-monitoring] schedule really helped them to know where their blood levels were and take appropriate action, such as adding physical activity or choosing a healthy snack," study author Dana Brackney, a diabetes educator and an assistant professor of nursing at Appalachian State University in Boone, N.C., said.
Blood sugar self-monitoring benefits patients with type 2 diabetes even if they are not prescribed insulin.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|